These findings with mice and rats indicate that pharmacological inhibition of NaCT might have therapeutic potential in the prevention of diet-induced obesity, hyperlipidemia, insulin resistance, and diabetes. This evidence concerns the gene SLC13A5 and diabetes mellitus.